Compounded Semaglutide Concerns From the FDA

Two sources describe compounded semaglutide, and they worry about different things. The federal regulator writes about dosing. Pharmacy Times writes about how compounding was allowed during a shortage and then wound down. This article lines the two up and marks where a claim can outrun either one.

What the FDA reports

Under the heading dosing concerns with compounded semaglutide and tirzepatide, www.fda.gov says it received multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors associated with compounded injectable semaglutide products.

The full page is titled concerns with unapproved GLP-1 drugs used for weight loss, and the word "unapproved" in that title matters as much as the dosing detail.

Lined up point by point

The regulator passage is about harm after use: reports of adverse events tied to dosing errors. The trade press passage is about supply and rules: who could make these versions, when, and for how long.

One is a safety observation. The other is a timeline. A reader comparing a clinic's compounded offer with an approved medicine needs both, and neither answers the other's question.

What the trade press reports

Per www.pharmacytimes.com, manufacturers of compounded tirzepatide and semaglutide had the ability to produce these versions while the drugs were on the FDA shortage list, and once they were removed, the FDA notified compounders that they had a transitional period to cease production.

That account runs in Pharmacy Times coverage of concerns surrounding compounded GLP-1s as shortages end.

Where a claim runs ahead of its source

In the regulator passage the wording is "may be related to" dosing errors. A page that says compounded products caused hospitalizations has gone beyond that wording. A menu that describes a compounded version as the same as an approved medicine is making a claim that neither passage makes.

The footnote to check before deciding

Read the FDA wording on dosing errors first, then ask any provider how a compounded product is dosed and labeled. If the answer leans on the shortage, check it against the transitional period described above.